Literature DB >> 32378445

Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers.

Olena Odnokoz1, Pengfei Yu1, Amy R Peck2, Yunguang Sun2, Albert J Kovatich3, Jeffrey A Hooke3, Hai Hu4, Edith P Mitchell5, Hallgeir Rui2, Serge Y Fuchs1.   

Abstract

Within the microenvironment of solid tumors, stress associated with deficit of nutrients and oxygen as well as tumor-derived factors triggers the phosphorylation-dependent degradation of the IFNAR1 chain of type I interferon (IFN1) receptor and ensuing suppression of the IFN1 pathway. Here we sought to examine the importance of these events in malignant mammary cells. Expression of non-degradable IFNAR1S526A mutant in mouse mammary adenocarcinoma cells stimulated the IFN1 pathway yet did not affect growth of these cells in vitro or ability to form subcutaneous tumors in the syngeneic mice. Remarkably, these cells exhibited a notably accelerated growth when transplanted orthotopically into mammary glands. Importantly, in human patients with either ER+ or ER- breast cancers, high levels of IFNAR1 were associated with poor prognosis. We discuss the putative mechanisms underlying the pro-tumorigenic role of IFNAR1 in malignant breast cells.

Entities:  

Keywords:  IFNAR1; PD-L1; breast cancer; immune therapy; interferon receptor; mammary adenocarcinoma; type I interferon

Year:  2020        PMID: 32378445      PMCID: PMC7515508          DOI: 10.1080/15384047.2020.1750297

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  41 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

2.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

3.  Polyoma virus disrupts ARF signaling to p53.

Authors:  M Lomax; M Fried
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

Review 4.  Adipose tissue and adipocytes support tumorigenesis and metastasis.

Authors:  Kristin M Nieman; Iris L Romero; Bennett Van Houten; Ernst Lengyel
Journal:  Biochim Biophys Acta       Date:  2013-03-14

5.  Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines.

Authors:  Vladislava O Melnikova; Svetlana V Bolshakov; Christopher Walker; Honnavara N Ananthaswamy
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

6.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.

Authors:  Ralph R Weichselbaum; Hemant Ishwaran; Taewon Yoon; Dimitry S A Nuyten; Samuel W Baker; Nikolai Khodarev; Andy W Su; Arif Y Shaikh; Paul Roach; Bas Kreike; Bernard Roizman; Jonas Bergh; Yudi Pawitan; Marc J van de Vijver; Andy J Minn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

7.  Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1.

Authors:  Juan Qian; Hui Zheng; Wei-Chun Huangfu; Jianghuai Liu; Christopher J Carbone; N Adrian Leu; Darren P Baker; Serge Y Fuchs
Journal:  PLoS Pathog       Date:  2011-06-09       Impact factor: 6.823

8.  Inflammatory signaling compromises cell responses to interferon alpha.

Authors:  W-C Huangfu; J Qian; C Liu; J Liu; A E Lokshin; D P Baker; H Rui; S Y Fuchs
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

9.  Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.

Authors:  Hailong Ma; Wenyi Yang; Liming Zhang; Shuli Liu; Mei Zhao; Ge Zhou; Lizhen Wang; Shufang Jin; Zhiyuan Zhang; Jingzhou Hu
Journal:  Br J Cancer       Date:  2018-12-17       Impact factor: 7.640

10.  Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.

Authors:  Bogang Wu; Xiujie Sun; Harshita B Gupta; Bin Yuan; Jingwei Li; Fei Ge; Huai-Chin Chiang; Xiaowen Zhang; Chi Zhang; Deyi Zhang; Jing Yang; Yanfen Hu; Tyler J Curiel; Rong Li
Journal:  Oncoimmunology       Date:  2018-08-23       Impact factor: 8.110

View more
  2 in total

1.  Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer.

Authors:  Damien J Zanker; Alex J Spurling; Natasha K Brockwell; Katie L Owen; Jasmine M Zakhour; Tina Robinson; Hendrika M Duivenvoorden; Paul J Hertzog; Stefanie R Mullins; Robert W Wilkinson; Belinda S Parker
Journal:  Clin Transl Immunology       Date:  2020-09-28

Review 2.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.